Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001
Development of mycobacterium tuberculosis additional drug resistance during chemotherapy of disseminated pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 663s Year: 2007
Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis Source: Eur Respir J , 49 (4) 1602215; DOI: 10.1183/13993003.02215-2016 Year: 2017
Efficiency of standard chemotherapy of patients with pulmonary TB with relapses and treatment failure at drug resistance of M. tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 339s Year: 2001
Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex-MycTB Source: Eur Respir J, 57 (1) 2001796; 10.1183/13993003.01796-2020 Year: 2021
The main clinical problem of increasing resistance of Mycobacterium tuberculosis (MT) to first-line anti-TB drugs Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005
Dependending on drug resistance character of bacteriostatic blood activity at time polychemotherapy against of M. tuberculosis strains isolated from patients Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002
Burden of the primary drug resistance of Mycobacterium tuberculosis in HIV-positive patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
Problem of resistance of mycobacterium tuberculosis to short-time standard combined chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 846s Year: 2006
Drug resistance profiles of mycobacterium tuberculosis isolates in MDR pulmonary tuberculosis from a high burden developing country Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
Changes in the metabolism of Mycobacterium tuberculosis during the course of TB treatment Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection Year: 2021
Characteristics of drug susceptibility testing for bedaquline and clofazimine of 178 drug-resistant Mycobacterium tuberculosis isolates in Japan Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Susceptibility of Mycobacterium tuberculosis strains to fluoquinolones, obtained from chronic patients with multidrug resistant pulmonary tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 315s Year: 2001
Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017
Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005
Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008
Resistance rates of Mycobacterium tuberculosis to first-line antituberculosis drugs. Trends in Greece during the period 1991–2000 Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003
Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004